Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients

NCT01020123 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01020123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01020123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
February 28, 2011
Enrollment
530 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

type ii diabetes mellitus